The National Security Commission on Emerging Biotechnology (NSCEB) announced on April 8, 2025, the availability of its final report and action plan, “urging Congressional action to bring the full ...

After months spent pursuing a plan to convert itself into a for-profit business, OpenAI is reversing course and said Monday ...

Positive Lexeo Therapeutics, Inc. interim data from SUNRISE-FA study highlights LX2006's potential for Friedreich's Ataxia.

Replimune Group, Inc.'s RP1 + OPDIVO for advanced melanoma gains FDA Priority Review. PDUFA date: July 22, 2025. Read more on ...

Among other steps to foster international cooperation with our friends and partners, the report recommends that Congress include biotech within the scope of the State Department’s International ...

The startup, Veraxa, has $253 million in cash and is raising a crossover funding round to support a pipeline of T-cell ...

Tim Friede has been bitten by hundreds of snakes. And now, scientists are studying his blood to create a universal antivenom.

Congressional commission urges $15B, more action to maintain US biotech advantage over China ... under the Biden administration, though its scope has changed under the Trump administration.

We have a responsibility to ensure that our discoveries are used in the public interest. That isn’t always easy.

What’s next: The commission recommends the U.S. prioritize biotechnology ... that can replace federal government funding. The scope is slightly different. The U.S. government has a role in ...

Request To Download Free Sample of This Strategic Report  @   This country research report on Vietnam Market offers comprehensive insights into the market landscape, customer intelligence, and ...

Wegovy and Zepbound, the two leading weight-loss drugs, together sold less than $5 billion in 2023, according to ...